Open AccessMyocardial Viability Imaging using Manganese‐Enhanced MRI in the First Hours after Myocardial Infarction
Author(s) -
Jasmin Nur Hayati,
Thin May Zaw,
Johnson Robert D.,
Jackson Laurence H.,
Roberts Thomas A.,
David Anna L.,
Lythgoe Mark F.,
Yang Philip C.,
Davidson Sean M.,
Camelliti Patrizia,
Stuckey Daniel J.
Publication year - 2021
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202003987
Subject(s) - myocardial infarction , medicine , contractility , magnetic resonance imaging , in vivo , cardiology , biomarker , gadolinium , radiology , chemistry , biology , biochemistry , microbiology and biotechnology , organic chemistry
Early measurements of tissue viability after myocardial infarction (MI) are essential for accurate diagnosis and treatment planning but are challenging to obtain. Here, manganese, a calcium analogue and clinically approved magnetic resonance imaging (MRI) contrast agent, is used as an imaging biomarker of myocardial viability in the first hours after experimental MI. Safe Mn 2+ dosing is confirmed by measuring in vitro beating rates, calcium transients, and action potentials in cardiomyocytes, and in vivo heart rates and cardiac contractility in mice. Quantitative T1 mapping‐manganese‐enhanced MRI (MEMRI) reveals elevated and increasing Mn 2+ uptake in viable myocardium remote from the infarct, suggesting MEMRI offers a quantitative biomarker of cardiac inotropy. MEMRI evaluation of infarct size at 1 h, 1 and 14 days after MI quantifies myocardial viability earlier than the current gold‐standard technique, late‐gadolinium‐enhanced MRI. These data, coupled with the re‐emergence of clinical Mn 2+ ‐based contrast agents open the possibility of using MEMRI for direct evaluation of myocardial viability early after ischemic onset in patients.